228 related articles for article (PubMed ID: 30171560)
1. Morpholino-Mediated Exon Inclusion for SMA.
Zhou H; Muntoni F
Methods Mol Biol; 2018; 1828():467-477. PubMed ID: 30171560
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
3. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy.
Shabanpoor F; Hammond SM; Abendroth F; Hazell G; Wood MJA; Gait MJ
Nucleic Acid Ther; 2017 Jun; 27(3):130-143. PubMed ID: 28118087
[TBL] [Abstract][Full Text] [Related]
5. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
7. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model.
Sheng L; Rigo F; Bennett CF; Krainer AR; Hua Y
Nucleic Acids Res; 2020 Apr; 48(6):2853-2865. PubMed ID: 32103257
[TBL] [Abstract][Full Text] [Related]
9. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
10. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.
Zhou H; Janghra N; Mitrpant C; Dickinson RL; Anthony K; Price L; Eperon IC; Wilton SD; Morgan J; Muntoni F
Hum Gene Ther; 2013 Mar; 24(3):331-42. PubMed ID: 23339722
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype.
Nizzardo M; Simone C; Salani S; Ruepp MD; Rizzo F; Ruggieri M; Zanetta C; Brajkovic S; Moulton HM; Müehlemann O; Bresolin N; Comi GP; Corti S
Clin Ther; 2014 Mar; 36(3):340-56.e5. PubMed ID: 24636820
[TBL] [Abstract][Full Text] [Related]
12. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
13. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.
Hara Y; Mizobe Y; Miyatake S; Takizawa H; Nagata T; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():553-564. PubMed ID: 30171567
[TBL] [Abstract][Full Text] [Related]
14. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
15. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.
Singh NK; Singh NN; Androphy EJ; Singh RN
Mol Cell Biol; 2006 Feb; 26(4):1333-46. PubMed ID: 16449646
[TBL] [Abstract][Full Text] [Related]
16. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
[TBL] [Abstract][Full Text] [Related]
17. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
18. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
